Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now early-phase tilt small index

Stage IVB Hepatocellular Carcinoma AJCC V8: early-phase trial registry

4 of 8 indexed Stage IVB Hepatocellular Carcinoma AJCC V8 trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,176 of 28,707 conditions by registered trial count.

8 US clinical trials · 4 currently recruiting · #2,176 of 28,707 conditions by registered trial count

Stage IVB Hepatocellular Carcinoma AJCC V8: 8 US clinical trials tracked, 4 recruiting.

Stage IVB Hepatocellular Carcinoma AJCC V8 is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is City of Hope Medical Center, running 2 of these trials.

Enrollment posture brief

Registry condition stage-ivb-hepatocellular-carcinoma-ajcc-v8

OPEN 4 | RECR 50% | LATE 0 | EARLY 7 | RANK #2176 | SPON 2

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Activity, Motor75%Achalasia50%Stage IVB Hepatocellular (th…50%Abdominal Cancer25%Acne Scars - Mixed Atrophic 25%
Open-enrollment share among volume-matched conditions near Stage IVB Hepatocellular Carcinoma AJCC V8

Stage IVB Hepatocellular Carcinoma AJCC V8 lists 4 open slots (50% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Stage IVB Hepatocellular Carcinoma AJCC V8 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Stage IVB Hepatocellular Carcinoma AJCC V8 is recruiting above its size-band peers.

    4 of 8 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Stage IVB Hepatocellular Carcinoma AJCC V8 research.

    City of Hope Medical Center accounts for 2 of 8 trials (25%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Most Stage IVB Hepatocellular Carcinoma AJCC V8 trials plan to enrol fewer than 100 people.

    Median target enrolment is 21 among the 8 trials that report a genuine target (sentinel values excluded). 7 of those (87.5%) plan for fewer than 100 participants.

  4. Stage IVB Hepatocellular Carcinoma AJCC V8 research is mostly interventional.

    8 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 24

Open and recent trials

8 total, page 1 of 1

RECRUITING Phase 2 122 participants

Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

Academic and Community Cancer Research United

NCT05168163

RECRUITING Phase 2 21 participants

Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma

Mary Feng, MD

NCT04430452

RECRUITING Phase 2 19 participants

Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

Emory University

NCT05103904

RECRUITING Phase 1 15 participants

Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer

M.D. Anderson Cancer Center

NCT04380545

ACTIVE NOT RECRUITING NA 42 participants

Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D)

M.D. Anderson Cancer Center

NCT03896646

ACTIVE NOT RECRUITING Phase 1 25 participants

Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer

City of Hope Medical Center

NCT04605731

ACTIVE NOT RECRUITING Phase 1 8 participants

IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer

City of Hope Medical Center

NCT03655002

COMPLETED Phase 2 16 participants

Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer

Robin Kate Kelley

NCT03439891

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 4

Named interventions

Most-linked intervention names on Stage IVB Hepatocellular Carcinoma AJCC V8 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Nivolumab Biological
3 trials
Tremelimumab Biological
2 trials
Lenvatinib Drug
2 trials
Durvalumab Biological
2 trials
Yttrium-90 Microsphere Radioembolization Procedure
1 trials
Yttrium Y 90 Glass Microspheres Radiation
1 trials
Hepatobiliary Iminodiacetic Acid Scan Other
1 trials
Cytokine-based Biologic Agent IRX-2 Biological
1 trials

US sites by state

Facility locations filed on Stage IVB Hepatocellular Carcinoma AJCC V8 trials. A trial with sites in several states counts in each.

California 4 trials
Texas 3 trials
Arizona 3 trials
Wisconsin 1 trials
South Dakota 1 trials
Pennsylvania 1 trials
Ohio 1 trials
New York 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Stage IVB Hepatocellular Carcinoma AJCC V8 page

8 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 4 Stage IVB Hepatocellular Carcinoma AJCC V8 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • City of Hope Medical Center sponsors the most Stage IVB Hepatocellular Carcinoma AJCC V8 trials on record, review their full trial history before evaluating a specific study. See City of Hope Medical Center's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage IVB Hepatocellular Carcinoma AJCC V8 condition card totals 8 registered trials; most-linked intervention Nivolumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.